Labrador Technologies Inc. announced that the reverse take-over transaction (the "Reverse Take-over" or "RTO") pursuant to the exclusive software license purchase agreement (the "Agreement") with Claritas HealthTech Pte. Ltd. ("Claritas") dated June 28, 2020 and as amended on May 24, 2021 will not be proceeding as conditions to closing have not been met by the outside closing date of July 15, 2021. As a result, the Company is now open to receive indications of interest from parties in respect of potential transactions, the Board believes this an opportune time to explore a wide range of options to ascertain if it can take advantage of Labrador's public listing and tax pools, with a focus on shareholder value (collectively, the "Strategic Review"). The Strategic Review is intended to explore a comprehensive range of strategic transaction alternatives. These alternatives include, but are not limited to, any one or a combination of the following: opportunities to selectively raise and deploy capital (within the technology sector or otherwise); and a merger or other business combination. The Strategic Review will continue the Company's restructuring efforts which have resulted in material reductions in capital and debt outstanding.